Keyphrases
ADNI-1
16%
Advanced Disease
8%
Advanced Stage
8%
Aging
8%
Alzheimer's Disease
100%
Alzheimer's Disease Diagnosis
8%
Amsterdam
8%
Apolipoprotein E
8%
Area under the Receiver Operating Characteristic Curve
8%
Atrophy
8%
Atrophy Rate
8%
Balanced Accuracy
8%
Baseline Data
8%
Cerebrospinal Fluid Samples
16%
Clinic-based
8%
Clinical Drug Trials
8%
Clinical Symptoms
8%
Clinician Decision Making
16%
Cognitive Dementia
16%
Cognitive Functioning
8%
Cognitive Tests
8%
Combined Information
8%
Comorbidity
8%
Cost-effectiveness
8%
Cox Proportional Hazards Model
8%
Data Modality
33%
Data Visualization Methods
8%
Data-driven Analysis
8%
Data-driven Methods
16%
Data-driven Visualization
8%
Decision Support
100%
Decision-making Process
8%
Dementia
33%
Dependent Tests
8%
Diagnostic Criteria
8%
Digit Span Backwards
8%
Disease Spectrum
8%
Disease Stage
8%
Disease States
58%
Disease-related
8%
Early Diagnosis
16%
Europe
8%
Examination Method
8%
Fingerprint Data
8%
Global Cortical Atrophy
8%
Healthcare
8%
Heterogeneous Patients
8%
Hippocampal Atrophy
8%
Imaging Biomarkers
8%
Indexing Methods
16%
Information Overload
8%
International Journals
8%
Lifestyle Intervention
8%
Longitudinal Data
16%
Longitudinal Profile
8%
Magnetic Resonance Imaging
25%
Magnetic Resonance Imaging Features
8%
Male Sex
8%
Medial Temporal Lobe Atrophy
8%
Medication Interventions
8%
Memory Clinic
8%
Method Validation
8%
Mild Cognitive Impairment
41%
Mild Stage
8%
Mortality Risk
8%
Most Common Form
8%
Multivariable Approach
100%
Negative Predictive Value
8%
Neurodegenerative Diseases
8%
Neuroimaging
8%
Neuropsychological Tests
8%
Normal Cognition
16%
Old Age
8%
One-group
8%
Optimal Combination
8%
Pathological Changes
8%
Patient Assessment
8%
Patient Data
8%
Patient Support
8%
Patient Well-being
8%
Patients with Dementia
8%
Penalized Regression
8%
Performance Prediction
8%
Positive Predictive Value
8%
Prediction Accuracy
8%
Real Change
8%
Severe Disease
8%
Stable Disease
8%
State Index
50%
Subjective Cognitive Decline
8%
Supervised Machine Learning
8%
Temporal Lobe
8%
Threonine
8%
Trail Making Test
8%
Validation Cohort
16%
Variable Combination
8%
Visualization Method
8%
INIS
accuracy
9%
aging
4%
apolipoproteins
4%
atrophy
23%
auc
9%
biological markers
9%
brain
4%
cerebrospinal fluid
9%
cost
4%
curves
4%
data
61%
data visualization
4%
death
4%
decision making
9%
diagnosis
4%
diseases
57%
drugs
4%
environment
4%
europe
4%
genetics
4%
hazards
4%
increasing
4%
information
14%
interventions
9%
levels
4%
machine learning
4%
males
4%
monitoring
100%
mortality
9%
nervous system diseases
100%
nmr imaging
19%
pathological changes
4%
patients
28%
performance
19%
populations
4%
prediction
100%
quality of life
4%
risks
4%
sex
14%
spectra
4%
symptoms
9%
threonine
4%
validation
14%
values
23%
Medicine and Dentistry
Alzheimer's Disease
100%
Apolipoprotein E
8%
Biological Marker
16%
Cerebrospinal Fluid
16%
Clinician
25%
Comorbidity
8%
Cost-Effectiveness Analysis
8%
Decision Making
16%
Degenerative Disease
8%
Diagnosis of Alzheimer's Disease
8%
Diseases
100%
Drug Screening
8%
Early Diagnosis
16%
Finger Dermatoglyphics
8%
Lifestyle Intervention
8%
Linear Regression Analysis
8%
Magnetic Resonance Imaging
33%
Medial Temporal Lobe
16%
Mild Cognitive Impairment
41%
Patient-Data
8%
Proportional Hazards Model
8%
Quality of Life
8%
Tau
8%
Biochemistry, Genetics and Molecular Biology
Apolipoprotein E
25%
Comorbidity
25%
Decision Making
50%
Drug Screening
25%
Genetics
25%
Magnetic Resonance Imaging
100%
Patient Coding
25%
Supervised Machine Learning
25%
Tau
25%
Threonine
25%
Neuroscience
Alzheimer's Disease
100%
Apolipoprotein E
7%
Cognitive Tests
7%
Comorbidity
7%
Decision-Making
7%
Decision-Making Process
7%
Magnetic Resonance Imaging
30%
Mild Cognitive Impairment
38%
Neurodegenerative Disorder
7%
Neuropsychological Test
7%
Subjective Cognitive Decline
7%
Temporal Lobe
15%
Threonine
7%